Fluoroquinolone Resistance and gyrA and parC Mutations of Escherichia coli Isolated from Chicken

• Published in: The journal of microbiology Vol. 43; no. 5; pp. 391 - 397
• Main Authors: Lee, Y.J. (Kyungpook National University, Daegu, Republic of Korea), E-mail: youngju@mail.knu.ac.kr, Cho, J.K. (Daegu Metropolitan City Research Institute of Health and Environment, Daegu, Republic of Korea), Kim, K.S. (Kyungpook National University, Daegu, Republic of Korea), Tak, R.B. (Kyungpook National University, Daegu, Republic of Korea), Kim, A.R. (National Veterinary Research and Quarantine Service, MAF, Anyang, Republic of Korea), Kim, J.W. (National Veterinary Research and Quarantine Service, MAF, Anyang, Republic of Korea), Im, S.K. (National Veterinary Research and Quarantine Service, MAF, Anyang, Republic of Korea), Kim, B.H. (National Veterinary Research and Quarantine Service, MAF, Anyang, Republic of Korea)
• Format: Journal Article
• Language: English
• Published: Korea (South) 한국미생물학회 01.10.2005
• Subjects: Animal Husbandry; Animals; Anti-Infective Agents - pharmacology; Chickens - microbiology; DNA Gyrase - genetics; DNA Topoisomerase IV - genetics; Drug Resistance, Bacterial - genetics; ESCHERICHIA COLI; Escherichia coli - drug effects; Escherichia coli - genetics; Escherichia coli - isolation & purification; Feces - microbiology; fluoroquinolone resistance; Fluoroquinolones - pharmacology; gyrA gene; Microbial Sensitivity Tests; Mutation; parC gene; 생물학
• ISSN: 1225-8873; 1976-3794

Escherichia coli is a common inhabitant of the intestinal tracts of animals and humans. The intestines of animals also represent an ideal environment for the selection and transfer of antimicrobial resistance genes. The aim of this study was to investigate the resistance of E. coli isolated from chicken fecal samples to fluoroquinolones and to analyze the characterization of mutations in its gyrA and parC gene related resistance. One hundred and twenty-eight E. coil isolates showed a high resistance to ciprofloxacin (CIP; 60.2%), enrofloxacin (ENO; 73.4%) and norfloxacin (NOR; 60.2%).